The Effects of Intradetrusor BoNT-A Injections on Vesicoureteral Reflux in Children With Myelodysplasia
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We retrospectively evaluated the efficacy of botulinum neurotoxin A (BoNT-A) on vesicoureteral reflux (VUR), continence status, and urodynamic parameters in children with myelodysplasia who were not responsive to standard conservative therapy. Methods: The study included 31 children (13 boys, 18 girls) with a mean age of 9.2±2.3 years (range, 5–14 years) with myelodysplasia, retrospectively. All children were fully compatible with clean intermittent catheterization (CIC) and did not respond to the maximum tolerable anticholinergic dose. All children received an intradetrusor injection of 10 U/kg (maximum, 300 U) of BoNT-A into an infection-free bladder. All patients had VUR (22 unilateral, 9 bilateral) preoperatively. The grade of reflux was mild (grades 1, 2), intermediate (grade 3), and severe (grades 4, 5) in 25, 7, and 8 ureters, respectively. Results: The mean maximum bladder capacity increased from 152.9±76.9 mL to 243.7±103 mL (P<0.001), and the maximum detrusor pressure decreased from 57±29.4 cm H2O to 29.6±13.9 cm H2O (P<0.001). After BoNT-A treatment, 16 refluxing ureters (40%) completely resolved, 17 (42.5%) improved, 5 (12.5%) remained unchanged, and 2 (5%) became worse. Of the 31 children with urinary leakage between CICs, 22 (71%) became completely dry, 6 (19%) improved, and 3 (10%) experienced partial improvement. Conclusions: In children with myelodysplasia, we were able to increase bladder capacity, enhance continence, and prevent VUR by using intradetrusor BoNT-A injections. Although our results are promising, a larger group of long-term prospective studies are warranted to investigate this method of treatment.
Abstract
Purpose: We retrospectively evaluated the efficacy of botulinum neurotoxin A (BoNT-A) on vesicoureteral reflux (VUR), continence status, and urodynamic parameters in children with myelodysplasia who were not responsive to standard conservative therapy. Methods: The study included 31 children (13 boys, 18 girls) with a mean age of 9.2±2.3 years (range, 5–14 years) with myelodysplasia, retrospectively. All children were fully compatible with clean intermittent catheterization (CIC) and did not respond to the maximum tolerable anticholinergic dose. All children received an intradetrusor injection of 10 U/kg (maximum, 300 U) of BoNT-A into an infection-free bladder. All patients had VUR (22 unilateral, 9 bilateral) preoperatively. The grade of reflux was mild (grades 1, 2), intermediate (grade 3), and severe (grades 4, 5) in 25, 7, and 8 ureters, respectively. Results: The mean maximum bladder capacity increased from 152.9±76.9 mL to 243.7±103 mL (P<0.001), and the maximum detrusor pressure decreased from 57±29.4 cm H2O to 29.6±13.9 cm H2O (P<0.001). After BoNT-A treatment, 16 refluxing ureters (40%) completely resolved, 17 (42.5%) improved, 5 (12.5%) remained unchanged, and 2 (5%) became worse. Of the 31 children with urinary leakage between CICs, 22 (71%) became completely dry, 6 (19%) improved, and 3 (10%) experienced partial improvement. Conclusions: In children with myelodysplasia, we were able to increase bladder capacity, enhance continence, and prevent VUR by using intradetrusor BoNT-A injections. Although our results are promising, a larger group of long-term prospective studies are warranted to investigate this method of treatment.
참고문헌 (25)
- Jeffs RD, "Surgical correction of vesicoureteral reflux in children with neurogenic bladder", J Urol, 115, pp.449~451 (1976)
- Seki N, "An analysis of risk factors for upper urinary tract deterioration in patients with myelodysplasia", BJU Int, 84, pp.679~682 (1999)
- Sidi AA, "Vesicoureteral reflux in children with myelodysplasia: natural history and results of treatment", J Urol, 136(1 Pt 2), pp.329~331 (1986)
- Morioka A, "Management of vesicoureteral reflux secondary to neurogenic bladder", Pediatr Surg Int, 13, pp.584~586 (1998)
- López Pereira P, "Should we treat vesicoureteral reflux in patients who simultaneously undergo bladder augmentation for neuropathic bladder?", J Urol, 165(6 Pt 2), pp.2259~2261 (2001)
- Engel JD, "Surgical versus endoscopic correction of vesicoureteral reflux in children with neurogenic bladder dysfunction", J Urol, 157, pp.2291~2294 (1997)
- Herbison P, "Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder : systematic review", BMJ, 326, pp.841~844 (2003)
- Thüroff JW, "EAU Guidelines on Urinary Incontinence", Actas Urol Esp, 35, pp.373~388 (2011)
- Rapp DE, "Botulinum toxin injection : a review of injection principles and protocols", Int Braz J Urol, 33, pp.132~141 (2007)
- Top T, "The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia", Neurourol Urodyn, 36, pp.1896~1902 (2017)
- Sekerci CA, "Value of urinary brain-derived neurotrophic factor levels on the assessment of botulinum toxin type A treatment for neurogenic detrusor overactivity in children with myelodysplasia", J Urol, 201, pp.174~180 (2019)
- Hascoet J, "Intradetrusor injections of botulinum toxin type A in children with spina bifida : a multicenter study", Urology, 116, pp.161~167 (2018)
- Lebowitz RL, "International system of radiographic grading of vesicoureteric reflux. International Reflux Study in Children", Pediatr Radiol, 15, pp.105~109 (1985)
- Lindehall B, "Effect of clean intermittent catheterisation on radiological appearance of the upper urinary tract in children with myelomeningocele", Br J Urol, 67, pp.415~419 (1991)
- Bauer SB, "Neurogenic bladder : etiology and assessment", Pediatr Nephrol, 23, pp.541~551 (2008)
- Merlini E, "Treatment of vesicoureteric reflux in the neurogenic bladder", Br J Urol, 72, pp.969~971 (1993)
- Kondo A, "Correction of reflux with the ureteric crossover method. Clinical experience in 50 patients", Br J Urol, 60, pp.36~38 (1987)
- Granata C, "Treatment of vesico-ureteric reflux in children with neuropathic bladder : a comparison of surgical and endoscopic correction", J Pediatr Surg, 34, pp.1836~1838 (1999)
- Perez-Brayfield M, "Endoscopic treatment with dextranomer", hyaluronic acid for complex cases of vesicoureteral reflux, 2004, pp.172(4 Pt 2), 1614~1616
- Neel KF, "Total endoscopic management(TEM approach)of children with non-compliant neuropathic bladder : a preliminary report", J Pediatr Urol, 4, pp.124~126 (2008)
- Schurch B, "Treatment of neurogenic incontinence with botulinum toxin A", N Engl J Med, 342, pp.665~ (2000)
- Karsenty G, "Botulinum toxin A(Botox)intradetrusor injections in adults with neurogenic detrusor overactivity", neurogenic overactive bladder : a systematic literature review, 2008, pp.53, 275~287
- Tufan Tarcan, "Intradetrusor Injections of Onabotulinum Toxin-A in Children With Urinary Incontinence due to Neurogenic Detrusor Overactivity Refractory to Antimuscarinic Treatment", Investigative and Clinical Urology, 55(4), pp.281~287 (2014), 대한비뇨의학회
- Schurch B, "Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence : results of a single treatment, randomized, placebo controlled 6-month study", J Urol, 174, pp.196~200 (2005)
- Mascarenhas F, "Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients", Neurourol Urodyn, 27, pp.311~314 (2008)